发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Patent highlights February-March 2024. 专利亮点2024年2月至3月。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-10-23 DOI: 10.1080/20468954.2024.2409624
Hermann Am Mucke
{"title":"Patent highlights February-March 2024.","authors":"Hermann Am Mucke","doi":"10.1080/20468954.2024.2409624","DOIUrl":"10.1080/20468954.2024.2409624","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 4-6","pages":"111-117"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights June - July 2024. 专利亮点2024年6月- 7月。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-03-07 DOI: 10.1080/20468954.2025.2459586
Hermann A M Mucke
{"title":"Patent highlights June - July 2024.","authors":"Hermann A M Mucke","doi":"10.1080/20468954.2025.2459586","DOIUrl":"10.1080/20468954.2025.2459586","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 4-6","pages":"125-129"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight. 治疗神经退行性疾病的磺胺丙酸衍生物：专利焦点。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-06-20 DOI: 10.1080/20468954.2024.2363657
Rami A Al-Horani
{"title":"Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight.","authors":"Rami A Al-Horani","doi":"10.1080/20468954.2024.2363657","DOIUrl":"10.1080/20468954.2024.2363657","url":null,"abstract":"<p><p>The patent introduces a class of agents that target amyloid aggregation, and subsequently, reduce amyloid β-oligomer neurotoxicity. The class encompasses sulfopropanoic acid derivatives and is represented by tramiprosate and its prodrug ALZ-801 (valiltramiprosate). Clinical trials showed that ALZ-801 oral tablet is well tolerated and showed superior pharmacokinetic properties in healthy volunteers and Alzheimer's disease (AD) patients. Results from phase II & III trials of ALZ-801 in early AD have provided evidence of efficacy and to adjudicate the role of amyloid β-oligomers in AD pathogenesis. The confirmatory APOLLOE4 phase III trial of ALZ-801 in APOE4/4 homozygotes with early AD has been initiated. If ALZ-801 is approved, it will be among the first oral disease-modifying drugs for AD.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 4-6","pages":"131-137"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PLGA and cancer: a comprehensive patent-based review on the present state of art. PLGA与癌症：基于专利的综合综述。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-03-01 DOI: 10.1080/20468954.2025.2470103
Venessa Nath, Mohini Singh, Bani Kumar Jana, Tumpa Sarkar, Niva Rani Gogoi, Bhaskar Mazumder
{"title":"PLGA and cancer: a comprehensive patent-based review on the present state of art.","authors":"Venessa Nath, Mohini Singh, Bani Kumar Jana, Tumpa Sarkar, Niva Rani Gogoi, Bhaskar Mazumder","doi":"10.1080/20468954.2025.2470103","DOIUrl":"10.1080/20468954.2025.2470103","url":null,"abstract":"<p><p>Poly (lactic-co-glycolic acid) (PLGA) is a highly efficient biodegradable polymeric nanoparticle (NP). Owing to its low toxicity, controlled and sustained release qualities, and biocompatibility with tissue and cells, the US FDA has approved its usage in drug delivery systems. The manufacturing and characterization techniques, surface changes, encapsulation of anticancer medicines, active or passive tumor targeting, and various PLGA nanoparticle release methods have been explored in the research arena in the past decade and patents have been filed across the globe. This review covers nanotechnology-backed PLGA patent literature for various types of cancers available on distinguished and eminent patent databases like 'Espacenet' and 'Patent Scope' ranging within a time frame from 2008 to 2024. This review is the first ever reported compilation of the state-of-the-art patent-based literature in PLGA nanoparticles. This review will pave a path for researchers of the present era and future, to understand the research landscape in PLGA nanoparticles and cancer therapy and pave a path for further connective research in the arena of PLGA-based nanoparticles and cancer formulation development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"201-215"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma. 双特异性抗cd38 /CD28抗体治疗多发性骨髓瘤。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-07-22 DOI: 10.1080/20468954.2025.2535944
Martin Perez-Santos, Maricruz Anaya-Ruiz, Donaciano Flores-Robles, Alejandro Millán-Vega, Pavel Sierra-Martínez
{"title":"Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma.","authors":"Martin Perez-Santos, Maricruz Anaya-Ruiz, Donaciano Flores-Robles, Alejandro Millán-Vega, Pavel Sierra-Martínez","doi":"10.1080/20468954.2025.2535944","DOIUrl":"10.1080/20468954.2025.2535944","url":null,"abstract":"<p><strong>Introduction: </strong>Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment.</p><p><strong>Areas covered: </strong>Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated <i>in vitro</i> cytotoxicity in tumor cells through increased proliferation of CD4+ and CD8+ cells, and the release of IFN-γ, IL-2, and TNF-α, as well as efficacy in a mouse model of multiple myeloma.</p><p><strong>Expert opinion: </strong>Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"175-180"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs. 美国专利局关于双重专利的相互矛盾的裁决危及仿制药和生物仿制药。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-02-08 DOI: 10.1080/20468954.2025.2459582
Sarfaraz K Niazi
{"title":"Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs.","authors":"Sarfaraz K Niazi","doi":"10.1080/20468954.2025.2459582","DOIUrl":"10.1080/20468954.2025.2459582","url":null,"abstract":"<p><p>Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs due to the legal complexity and cost burden of resolving patent thickets accumulated by the originator companies. The United States Patent and Trademark Office (USPTO) proposed a change in the ruling in March 2024 to avoid double patenting if the patent to which it is tied in terminal disclaimer has any claims that have been invalidated as anticipated or obvious. This rule change aimed to promote innovation and competition by deterring strategies that leverage multiple patents for obvious variants to obstruct competitors. However, after receiving 349 comments on the proposed rule change, the USPTO withdrew its plan in December 2024 despite most comments favoring it. In a contrary move, the USPTO secured a court ruling that the terminal disclaimers do not apply to extended patent expiry due to the failure of the USPTO to prosecute a patent on a timely basis. The double patenting must end to enable more affordable generic and biosimilar drugs.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"95-103"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development in medicinal chemistry via oxadiazole derivatives: patent spotlight 2020-2024. 恶二唑衍生物药物化学的发展：专利焦点2020-2024。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-05-07 DOI: 10.1080/20468954.2025.2500810
Mehwish Solangi, Fouzia Naz, Syed Abid Ali, Khalid Mohammed Khan
{"title":"Development in medicinal chemistry <i>via</i> oxadiazole derivatives: patent spotlight 2020-2024.","authors":"Mehwish Solangi, Fouzia Naz, Syed Abid Ali, Khalid Mohammed Khan","doi":"10.1080/20468954.2025.2500810","DOIUrl":"10.1080/20468954.2025.2500810","url":null,"abstract":"<p><p>The oxadiazole derivatives are part of the azole family and have drawn significant interest in medicinal chemistry due to their wide range of biological activities and promising pharmacological profiles. This patent spotlight highlights the developments of the oxadiazole-based compounds reported between 2020 and 2024, with applications in treating diseases such as cancer, bacterial infections, metabolic disorders, and neurodegenerative conditions. These compounds act through various mechanisms, including enzyme inhibition, receptor modulation, and disruption of microbial and cancer cell pathways. Their structural flexibility allows for the design of novel molecules targeting specific therapeutic areas. The spotlight on these recent patents underscores oxadiazole derivatives' growing importance in drug discovery, offering potential advancements in efficacy and safety for future therapeutic agents.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"139-148"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights June-July 2023. 2023 年 6 月至 7 月的专利亮点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.4155/ppa-2023-0035
Hermann Am Mucke
{"title":"Patent Highlights June-July 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0035","DOIUrl":"10.4155/ppa-2023-0035","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"7-14"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights August-September 2023. 2023 年 8 月至 9 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.4155/ppa-2023-0039
Hermann Am Mucke
{"title":"Patent highlights August-September 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0039","DOIUrl":"https://doi.org/10.4155/ppa-2023-0039","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"15-22"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care. 针对成纤维细胞活化蛋白的个体化癌症治疗的专利聚光灯。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-05-06 DOI: 10.1080/20468954.2025.2500811
Jason A Witek, Allen F Brooks, Benjamin L Viglianti, Peter J H Scott
{"title":"Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care.","authors":"Jason A Witek, Allen F Brooks, Benjamin L Viglianti, Peter J H Scott","doi":"10.1080/20468954.2025.2500811","DOIUrl":"10.1080/20468954.2025.2500811","url":null,"abstract":"<p><p>Theranostics represents the state-of-the-art in precision oncology treatment, and is gaining momentum because of the potential to help improve outcomes for even late-stage cancer patients. Pairs of identical (or very similar) molecules are labeled with both diagnostic and therapeutic radionuclides, and used to both image and treat cancer. The FDA approval and commercialization of theranostics for neuroendocrine tumors and prostate cancer has spurred development of new theranostics as well as significant venture and pharma investment, such that both academic medical centers and companies are working to advance the field. One theranostic target of interest is the Fibroblast Activation Protein (FAP) because its expression in many different tumor types offers potential for a pan-cancer theranostic. In this <i>Patent Spotlight</i>, we present the first analysis of patents issued for FAP-targeting radiopharmaceuticals, providing perspective on current trends and challenges as well as future directions.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"149-160"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信